More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.64B
EPS
-1.5
P/E ratio
--
Price to sales
378.58
Dividend yield
--
Beta
1.752972
Previous close
$17.27
Today's open
$17.20
Day's range
$16.39 - $17.42
52 week range
$6.17 - $21.27
show more
CEO
Sanjiv K. Patel
Employees
202
Headquarters
Cambridge, MA
Exchange
NASDAQ Global Market
Shares outstanding
220959470
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Relay Therapeutics, Inc. (RLAY) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Relay Therapeutics, Inc. ( RLAY ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 4:30 PM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Donald Bergstrom - President of Research & Development Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities, LLC Presentation Debjit Chattopadhyay Guggenheim Securities, LLC All right. Good afternoon.
Seeking Alpha • Nov 11, 2026

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition; Relay to hold conference call to discuss data and provide regulatory update Shannon Campbell to lead commercial preparations for zovegalisib in breast cancer and vascular anomalies Announced second vascular anomalies program for mutant-selective TIE2 inhibitor Approximately $849 million in cash, cash equivalents and investments at end of Q3 2026 CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today reported third quarter 2026 financial results and corporate updates.
GlobeNewsWire • Nov 4, 2026

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in three upcoming fireside chats in November:
GlobeNewsWire • Nov 2, 2026

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026.
GlobeNewsWire • Oct 28, 2026

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
CNBC Television • Oct 6, 2026

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 16, 2026

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Seeking Alpha • Sep 10, 2026

Relay Therapeutics CFO Sells 17,717 Shares for $350,000
The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.
The Motley Fool • Sep 2, 2026

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
GlobeNewsWire • Sep 1, 2026

This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.
Investors Business Daily • Aug 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Relay Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.